onkoserv

aktuelle literatur

Hier sehen Sie einige ausgewählte Beispielbeiträge aus unserer Datenbank.

26.10.2012

Long-term outcomes after high dose therapy and autologous haematopoietic cell rescue for refractory/relapsed Hodgkin lymphoma

Indikationen:
Hodgkin-Lymphom, Stammzellmobilisierung, Stammzelltransplantation

Comparison of a Strategy Favoring Early Surgical Resection vs a Strategy Favoring Watchful Waiting in Low-Grade Gliomas

Indikationen:
Gliom

Patients' Expectations about Effects of Chemotherapy for Advanced Cancer

Indikationen:
Kolorektales Karzinom, NSCLC
21.08.2012

Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: A randomized double-blind placebo controlled trial

Indikationen:
Mammakarzinom
Substanzen:
Omega-3-Fettsäuren
20.08.2012

The Price We Pay for Progress: A Meta-Analysis of Harms of Newly Approved Anticancer Drugs

Indikationen:
Solide Tumore
Substanzen:
Zytostatika generell
17.08.2012

Prevention of Pegfilgrastim-Induced Bone Pain: A Phase III Double-Blind Placebo-Controlled Randomized Clinical Trial of the University of Rochester Cancer Center Clinical Community Oncology Program Research Base

Indikationen:
Mammakarzinom, NSCLC, Solide Tumore
Substanzen:
G-CSF, pegyliert
16.08.2012

External Pelvic and Vaginal Irradiation Versus Vaginal Irradiation Alone as Postoperative Therapy in Medium-Risk Endometrial Carcinoma: A Prospective, Randomized Study-Quality-of-Life Analysis

Indikationen:
Endometriumkarzinom
Substanzen:
Radiotherapie
13.08.2012

Extended Benefit from Sequential Administration of Docetaxel after Standard Fluorouracil, Epirubicin, and Cyclophosphamide Regimen for Node-Positive Breast Cancer: The 8-Year Follow-Up Results of the UNICANCER-PACS01 Trial

Indikationen:
Mammakarzinom
Substanzen:
5-Fluorouracil, Docetaxel, Cyclophosphamid, Epirubicin
10.08.2012

Assessment of quality of life in advanced breast cancer. An overview of randomized phase III trials

Indikationen:
Mammakarzinom
09.08.2012

Outcomes of women with early-stage breast cancer receiving adjuvant trastuzumab

Indikationen:
Mammakarzinom
Substanzen:
Trastuzumab